"We are excited we can continue our initial collaboration with the EU Lead Factory and its European Screening Centre researchers in Oss, Oxford and Newhouse, which has yielded a screenable assay for one of the critical Dengue virus proteins. Having the EU Lead Factory as part of our concerted effort to generate preclinical candidates for Dengue is welcome support for Effecta and the patients suffering from this disease”, Effecta’s Directors Helmuth van Es and Paul Edwards said.
